| アブストラクト | OBJECTIVE: To compare healthcare resource utilisation (HCRU) and direct costs between responders versus non-responders to advanced therapies for rheumatoid arthritis (RA). METHODS: Patients initiating >/=1 advanced therapy (October 2018 - September 2019) with >/=1 RA claim (6-month pre-index period), >/=2 RA claims (any period), and >/=12 months follow-up were identified from the Medical Data Vision claims database. HCRU and all-cause and RA-related costs [direct medical, emergency department (ED), laboratory, and pharmacy] were compared between responders and non-responders. Adjusted incidence rate ratios (IRRs) for HCRU or cost were calculated via multivariable analyses. RESULTS: Among 2446 patients [non-responders (n = 1817); responders (n = 629)], non-responders had significantly longer hospitalisation days [IRR: 1.8 (95% CI: 1.2 - 2.6)], and significantly more ED visits [2.5 (1.5 - 4.2)] and prescriptions [1.1 (1.1 - 1.2)]. Mean all-cause hospital/outpatient medical costs were significantly higher for non-responders [1.4 (1.3 - 1.6), yen530,895 versus yen357,009 ($3992 versus $2684) for responders; yen173,886 ($1307) difference]; RA-related medical costs showed a similar trend [ yen351,306 vs yen253,030 ($2641 vs $1902); yen98,276 ($739) difference]. No differences between responders and non-responders were observed in mean all-cause and RA-related pharmacy costs. CONCLUSIONS: Non-responders to advanced therapies had greater HCRU and all-cause/RA-related direct costs as compared with responders, suggesting a need for more effective RA therapies to reduce the economic burden associated with non-response. |
|---|
| ジャーナル名 | Modern rheumatology |
|---|
| Pubmed追加日 | 2023/11/11 |
|---|
| 投稿者 | Ikeda, Kei; Kaneko, Yuko; Tsujita, Yuki; Kawaguchi, Isao; Patel, Jayeshkumar; Yamazaki, Toru; Fang, Siran; Kawahito, Yutaka |
|---|
| 組織名 | Department of Rheumatology, Dokkyo Medical University, Tochigi, Japan.;Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba;University, Chiba, Japan.;Division of Rheumatology, Department of Internal Medicine, Keio University School;of Medicine, Tokyo, Japan.;AbbVie GK, Tokyo, Japan.;AbbVie Inc., North Chicago, IL, USA.;Inflammation and Immunology, Graduate School of Medical Science, Kyoto;Prefectural University of Medicine, Kyoto, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37949632/ |
|---|
